Literature DB >> 8666994

Chimeric D2/D3 dopamine receptors efficiently inhibit adenylyl cyclase in HEK 293 cells.

S W Robinson1, M G Caron.   

Abstract

Despite a high degree of sequence homology, the dopamine D2 and D3 receptors have substantially different second messenger coupling properties. We have used chimeric D2/D3 receptors to investigate the contribution of the intracellular loops to the signaling properties of these receptors. In HEK 293 cells, D2 receptors inhibit prostaglandin E1-stimulated cyclic AMP levels by >90%, whereas D3 receptors inhibit cyclic AMP accumulation by only 20%. In chimeras that have the second or third intracellular loop, or both loops simultaneously, switched between the D2 and D3 receptors, the maximal inhibition of adenylyl cyclase is 60-90%. In addition, the potency of quinpirole to inhibit adenylyl cyclase activity at some of the chimeras is altered compared with the wild-type receptors. It appears that the intracellular loops of the D3 receptor are capable of interacting with G proteins, as when these loops are expressed in the D2 receptor, the chimeras inhibit adenylyl cyclase similarly to the wild-type D2 receptor. Our data suggest that the overall conformation of the D3 receptor may be such that it interacts with G proteins only weakly, but when the intracellular loops are expressed in another context or the D3 receptor structure is altered by the introduction of D2 receptor sequence, this constraint may be lifted.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8666994     DOI: 10.1046/j.1471-4159.1996.67010212.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  9 in total

1.  Coupling of dopamine receptors to G proteins: studies with chimeric D2/D3 dopamine receptors.

Authors:  Tal Ilani; C Simone Fishburn; Berta Levavi-Sivan; Shari Carmon; Lily Raveh; Sara Fuchs
Journal:  Cell Mol Neurobiol       Date:  2002-02       Impact factor: 5.046

2.  The N-terminal region of the dopamine D2 receptor, a rhodopsin-like GPCR, regulates correct integration into the plasma membrane and endocytic routes.

Authors:  D I Cho; C Min; K S Jung; S Y Cheong; M Zheng; S J Cheong; M H Oak; J H Cheong; B K Lee; K M Kim
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  β-arrestin2 plays permissive roles in the inhibitory activities of RGS9-2 on G protein-coupled receptors by maintaining RGS9-2 in the open conformation.

Authors:  Mei Zheng; Sang-Yoon Cheong; Chengchun Min; Mingli Jin; Dong-Im Cho; Kyeong-Man Kim
Journal:  Mol Cell Biol       Date:  2011-10-17       Impact factor: 4.272

4.  Characterization of mouse striatal precursor cell lines expressing functional dopamine receptors.

Authors:  Kiyomi Y Araki; Satoshi Fujimura; Marcy E MacDonald; Pradeep G Bhide
Journal:  Dev Neurosci       Date:  2006       Impact factor: 2.984

5.  Cocaine exposure modulates dopamine and adenosine signaling in the fetal brain.

Authors:  Regina C C Kubrusly; Pradeep G Bhide
Journal:  Neuropharmacology       Date:  2009-09-16       Impact factor: 5.250

6.  Dopamine receptor mRNA and protein expression in the mouse corpus striatum and cerebral cortex during pre- and postnatal development.

Authors:  Kiyomi Y Araki; John R Sims; Pradeep G Bhide
Journal:  Brain Res       Date:  2007-04-22       Impact factor: 3.252

7.  Leu128(3.43) (l128) and Val247(6.40) (V247) of CXCR1 are critical amino acid residues for g protein coupling and receptor activation.

Authors:  Xinbing Han; Souvenir D Tachado; Henry Koziel; William A Boisvert
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

Review 8.  Recent methods for measuring dopamine D3 receptor occupancy in vivo: importance for drug development.

Authors:  Bernard Le Foll; Alan A Wilson; Ariel Graff; Isabelle Boileau; Patricia Di Ciano
Journal:  Front Pharmacol       Date:  2014-07-10       Impact factor: 5.810

9.  Roles of Dopamine D₂ Receptor Subregions in Interactions with β-Arrestin2.

Authors:  Xiaohan Zhang; Bo-Gil Choi; Kyeong-Man Kim
Journal:  Biomol Ther (Seoul)       Date:  2016-09-01       Impact factor: 4.634

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.